Corvus Pharmaceuticals (NASDAQ: CRVS) shares more than doubled on Jan. 20 after announcing positive Phase 1 trial data for “soquelitinib” – its oral investigational drug for atopic dermatitis.Soquelitinib demonstrated strong efficacy in treatment-resistant patients and a “favourable” safety profile, sparking chatter about “best-in-class” potential in the massive dermatology market.Following today’s…
Apple stock (NASDAQ: AAPL) slid nearly 3% on Tuesday, even as Evercore and Citi issued constructive notes ahead of…
BigBear.ai (NYSE: BBAI stock) tumbled on Tuesday after Pomerantz LLP, a prominent securities law firm, announced it is investigating…
Netflix (NASDAQ: NFLX) shares are trending down in after-hours after the streaming behemoth reported its financials for the fourth…
Gold price has ended the week-long range-bound trading by refreshing its all-time high earlier on Tuesday. At the time…
Asian financial markets remained under pressure on Wednesday as geopolitical tensions linked to US President Donald Trump’s comments on…
The Tesco share price pulled back and moved into a correction, falling by 11% from its highest level in…
Victoria, Seychelles, January 21, 2026—Bitget, the world’s largest Universal Exchange (UEX), has released its latest research whitepaper, Bitget Universal…
US spot Bitcoin and Ether exchange-traded funds recorded heavy net outflows on Tuesday, reflecting the intensifying macro-driven selloff that…